Search

Tributyltin chloride (TBTC) is well known for its immunotoxic effect, in particular towards immature thymocytes. TBTC is also known to induce adipocyte differentiation in primary human bone marrow cultures, which is reflected in the decrease in a number of adipocyte-derived cytokines, chemokines and the adipocyte-linked hormone leptin. Since adipocytes influence haematopoiesis and lymphopoiesis for instance by these cytokines and hormones, we here investigated whether TBTC has an effect on specific lymphocyte subsets in human bone marrow primary cultures. FACS analysis showed a reduction of CD19/CD22-positive B cells by TBTC, both in the presence or absence of cytokines. The treatment did not cause a toxic effect on mature CD3+CD4+ and CD3+CD8+ T cells, suggesting selective TBTC toxicity on B lymphocytes in the presently used in vitro system.

Immunotoxicity of xenobiotics is of growing concern for various levels in society, including industry and regulatory authorities. Despite that EU legislation aims at reducing the number of laboratory animals by promoting the development of alternative validated methods. At present, immunotoxicity is generally evaluated through standard in vivo toxicity studies. The lack of alternative methods is due, in particular, to the complexity of the immune system and its responses, but possibly alternative methods for immunosuppressive chemicals are most achievable. The present study describes a long term culture (LTC) method capable of inducing the formation of lymphocyte subsets from human mononuclear bone marrow cells that may allow evaluation of lymphotoxicity. The LTC consisted of two stages: a myeloid stage to allow the formation of a stromal layer and a lymphoid stage to allow expansion of lymphocytes. Results show that the use of IL-7 in LTC inhibits precursor and mature B cells, while it supports the proliferation of CD3+CD8+ and CD3+CD4+ T-cells. The bone marrow LTC model may in future be used to test the effect of xenobiotics on stromal dependent lymphocyte formation., JRC.I.2-Validation of Alternative Methods